A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

NCT03798366 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis

Interventions

DRUG: GLPG1690
DRUG: Placebo

Sponsor

Lakefront Biotherapeutics NV